US Patent 8,143,283: Scope, Claim Architecture, and US Landscape for Oral Thalidomide Dosing in Blood-Born Tumors and Leukemia
What do the independent and dependent claims cover?
US Drug Patent 8,143,283 is a method-of-treatment patent centered on oral administration of thalidomide in capsule form at specific daily dose ranges, aimed at blood-borne tumors (independent claim 1) and leukemia (independent claim 3). Dependent claims 2 and 4 narrow dose ranges, and claim 5 adds an explicit anti-angiogenic framing and “anti-angiogenic amount” language.
Claim set (as provided)
| Claim |
Target indication |
Route / form requirement |
Dose range requirement |
Claim type / key limitation |
| 1 |
Blood-born tumor |
Oral administration of thalidomide in a capsule |
0.5 to 50 mg/kg/day |
Independent method claim |
| 2 |
Blood-born tumor (same as claim 1) |
Capsule |
1 to 10 mg/kg/day |
Dependent dose narrowing |
| 3 |
Leukemia |
Oral administration of thalidomide in a capsule |
0.5 to 50 mg/kg/day |
Independent method claim |
| 4 |
Leukemia (same as claim 3) |
Capsule |
1 to 10 mg/kg/day |
Dependent dose narrowing |
| 5 |
Blood-born tumor |
“Capsule of thalidomide” |
Anti-angiogenic amount of 0.5 to 50 mg/kg/day |
Independent-ish scope expansion tied to anti-angiogenesis |
Core claim architecture
Across claims 1 and 3, the patent’s scope is built from three stacked limitations:
- Condition: blood-borne tumor or leukemia (broad clinical categories as written).
- Product form and administration: thalidomide delivered orally and specifically in capsule form.
- Dosage window: 0.5 to 50 mg/kg/day, with a narrower 1 to 10 mg/kg/day window in dependent claims.
Claim 5 keeps the same capsule and dose framework, but adds an anti-angiogenic amount requirement paired with an anti-angiogenic agent against the tumor statement. In scope terms, that typically operates as an additional tie to mechanism-of-action or intended use language rather than a new dosing parameter, but it still can matter for claim construction and infringement arguments depending on how a court reads “anti-angiogenic amount.”
Where is the claim scope broad, and where is it narrow?
Broadest elements
- Oral route: any oral capsule administration falls within the method claims.
- Dose ceiling and floor: 0.5 to 50 mg/kg/day is wide. For many oncology dosing paradigms, this is a comparatively large band, which increases infringement surface area for clinicians and label-adjacent regimens.
- Indication class language: “blood-born tumor” is not enumerated species-specific and “leukemia” is also broad as written. Those phrases can capture diverse hematologic malignancies that are “blood-related.”
Narrowest elements
- Capsule form constraint: the claims explicitly require thalidomide administered “in a capsule.” That can exclude:
- oral solutions/suspensions
- tablets if not treated as “capsules” under construction (a litigation risk for generic manufacturers and formulators)
- administered forms other than capsule
- Dose narrowing claims 2 and 4: 1 to 10 mg/kg/day is narrower and only applies in the dependent branches.
- Anti-angiogenic framing in claim 5: while the numeric dosing window matches claims 1 and 5’s base range, the phrase “anti-angiogenic amount” can invite disputes over whether any effective anti-angiogenic effect is required, or whether it is satisfied by the intended use as written.
How does the dosing window map to infringement risk?
The numeric scope is defined in mg/kg/day, not “mg,” “mg/day,” or fixed dosing. That matters because infringement can be evaluated patient-specifically. A regimen using a mg-per-day that falls into the window depending on patient weight can still align with the claim language.
Numeric bands in the claims
| Band |
Claims |
Scope implication |
| 0.5 to 50 mg/kg/day |
Claims 1 and 3; also appears in claim 5 as the anti-angiogenic amount |
Very wide method scope. Clinically, it can cover low, medium, and high dose regimens depending on patient weight. |
| 1 to 10 mg/kg/day |
Claims 2 and 4 |
A narrower “sweet spot” region. If an accused regimen stays strictly outside this band, it may avoid dependent-claim infringement but still fall under independent claims unless dose remains outside 0.5 to 50 mg/kg/day. |
Practical infringement patterns
- Accused regimen in 0.5 to 50 mg/kg/day with oral capsule thalidomide for leukemia: strongly within claims 3 and likely claims 1 if the leukemia is argued as a “blood-born tumor” within the claim language.
- Accused regimen in 0.1 to 0.49 mg/kg/day: avoids independent claims on the dosing floor.
- Accused regimen in >50 mg/kg/day: avoids independent claims on the dosing ceiling, but could still create separate exposure under other patents if they exist.
- Accused regimen uses non-capsule oral forms (e.g., tablets or liquid): can avoid the capsule requirement if “capsule” is construed narrowly.
How does claim 5 change the legal and technical scope?
Claim 5 adds:
- “anti-angiogenic amount”
- thalidomide as an anti-angiogenic agent against said tumor
- same numeric range 0.5 to 50 mg/kg/day
- still requires capsule and oral administration (capsule explicitly; route is implicit but tied to administration of a capsule)
Scope impact
- Numeric scope does not expand beyond claim 1: the range is the same.
- Mechanistic language can broaden or narrow depending on claim construction:
- If “anti-angiogenic amount” is interpreted functionally (dose sufficient to achieve anti-angiogenic effect), then a regimen at that dose may still infringe even if the label or clinician intent is different.
- If it is treated as an intended use limitation (the patient is administered as an anti-angiogenic agent), then real-world labeling and physician rationale become relevant.
In enforcement terms, claim 5 can help the patentee argue that thalidomide at that dose for a blood-borne tumor is used for anti-angiogenesis, reinforcing relevance to hematologic solid-tumor analogs and vascular tumor biology arguments.
What is the expected US patent landscape around this claim set?
High-level landscape drivers (based on the claim content)
Without relying on specific bibliographic entries here, the patent landscape for this subject matter in the US typically clusters around:
- Thalidomide’s oncology/hematology uses (method-of-treatment patents for leukemia and other hematologic malignancies).
- Dosing regimens and dose ranges.
- Formulation and administration patents (capsules vs other dosage forms).
- Anti-angiogenic mechanism in oncology method claims.
- Regulatory and formulation exclusivities affecting practical market timing even where patent claims vary.
Because 8,143,283 is explicitly a method claim with an administration form and dosing window, the most relevant prior art and design-around actions usually come from:
- earlier method patents using thalidomide orally and/or in a capsule
- earlier disclosures using mg/kg/day dosing ranges
- earlier claims covering blood-borne tumors or leukemia broadly
- earlier formulation claims ensuring oral capsule delivery of thalidomide
Most likely overlapping claim themes in earlier or later US patents
| Theme |
Why it matters for 8,143,283 |
| Oral thalidomide for leukemia |
Directly overlaps with claim 3 and often with claim 1 if leukemia is framed as blood-borne tumor |
| Dose-ranging disclosures (mg/kg/day) |
Overlaps with claims 1-4 and may create obviousness or anticipation issues |
| Capsule dosage form |
Can create formulation-specific overlap and design-around opportunities |
| Anti-angiogenic use |
Supports claim 5 and overlaps with angiogenesis-targeted thalidomide method claims |
| Hematologic tumor definitions |
“Blood-born tumor” breadth can overlap with earlier leukemia/lymphoma/marrow malignancy claims |
Where are the main design-arounds?
1) Dosage window changes
- Stay below 0.5 mg/kg/day to avoid claims 1 and 3.
- Stay above 50 mg/kg/day to avoid claims 1 and 3.
- Stay outside 1 to 10 mg/kg/day to avoid dependent claims 2 and 4, but independent claims remain unless also outside 0.5 to 50 mg/kg/day.
2) Dosage form changes
- Use a non-capsule oral form if “capsule” can be construed narrowly (e.g., tablet vs capsule).
- Use an administration route that is not “orally administering… in a capsule” (though many commercial strategies still rely on oral forms).
3) Indication shaping
Method-of-treatment patents often require that the accused use align with the claimed indication. However, with “blood-born tumor” and “leukemia” as written, clinicians may be able to map many malignancies into these categories. Design-around by indication typically requires strict alignment to avoid the claimed disease categories as construed.
Likelihood map by claim coverage
| Scenario |
Claim risk assessment (based on literal limitations) |
| Oral capsule thalidomide at 0.5 to 50 mg/kg/day for leukemia |
High: hits claim 3; also plausibly claim 1 if leukemia is treated as a blood-born tumor |
| Oral capsule at 1 to 10 mg/kg/day for leukemia |
Higher: hits claim 3 and dependent claim 4 |
| Oral capsule at 0.3 mg/kg/day for leukemia |
Lower: outside 0.5 mg/kg/day floor, avoids claim 3 |
| Oral thalidomide in tablet form at 1 to 10 mg/kg/day for leukemia |
Depends on “capsule” construction, but lower if tablet is excluded |
| Oral capsule at 0.5 to 50 mg/kg/day for a vascular-angiogenesis-related hematologic tumor |
Moderate to high: claim 1 and 5 exposure depends on whether disease fits “blood-born tumor” and whether the regimen is treated as anti-angiogenic |
What does the claim set imply about prosecution intent and claim strategy?
The claims show a strategy of pairing:
- a known active (thalidomide),
- with clinical-use method framing (treating blood-borne tumor/leukemia),
- with administration and formulation specificity (capsule, oral),
- and with broad-but-definable dosing ranges in mg/kg/day.
This is typical of patents aiming to secure enforceable method coverage around clinical practice patterns, where generic thalidomide itself may not be patentable but how it is prescribed can be.
Key Takeaways
- US 8,143,283 covers method-of-treatment use of thalidomide given orally as a capsule at 0.5 to 50 mg/kg/day for blood-borne tumors (claim 1) and leukemia (claim 3).
- Dependent claims add a narrower band of 1 to 10 mg/kg/day for the same indications (claims 2 and 4).
- Claim 5 keeps the same capsule and numeric range but adds anti-angiogenic amount and an anti-angiogenic framing against the tumor, supporting a mechanism-tied enforcement theory.
- The capsule limitation is the primary design-around lever; the dose window is the second. Staying outside 0.5 to 50 mg/kg/day is the cleanest way to avoid the independent claims.
FAQs
-
Does the patent cover thalidomide tablets or only capsules?
The claims require administration “in a capsule,” so tablets are not textually covered.
-
Are the leukemia claims limited to specific leukemia types?
The claim language is not type-specific; it covers “leukemia” broadly.
-
What dose range avoids claims 1 and 3?
Any regimen below 0.5 mg/kg/day or above 50 mg/kg/day avoids the independent-claim dose window as written.
-
Is claim 5 just repeating claim 1 with different wording?
It repeats the capsule and numeric dose range but adds “anti-angiogenic amount” and anti-angiogenic use language, which can change infringement analysis depending on construction.
-
If a clinician uses 1 to 10 mg/kg/day for leukemia, which claims are implicated?
Claims 3 (base leukemia method at 0.5 to 50 mg/kg/day) and 4 (dependent 1 to 10 mg/kg/day).
References (APA)
[1] US Patent 8,143,283. Method for treating blood-born tumor and leukemia using oral thalidomide in a capsule with specified mg/kg/day dosing ranges.
